Clinical trials: ctDNA
Cancer
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)
ASCEND-PANCREATIC is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, circulating tumor DNA (ctDNA) mutation, serum protein markers…
- Trial name
- NCT05556603
- Where
- 3 sites in China
- Volunteers
- 7,062 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Breast Cancer, Neoadjuvant Chemotherapy
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Breast cancer is the most common malignant tumor in women worldwide,and there exist a large part of patients need to receive neoadjuvant chemotherapy(NAC) before the curative surgery.Circulating tumor DNA(ctDNA) is the…
- Conditions
- Breast Cancer, Neoadjuvant Chemotherapy, Circulating Tumor DNA
- Trial name
- NCT03688035
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zhiyong Yu
Lung Cancer
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity and specificity.
- Trial name
- NCT04814407
- Testing
- Blood-derived DNA methylation detection
- Where
- Taiwan
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer
A Prospective Cohort Study on Colorectal Cancer Screening in Community Population
This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort.
- Trial name
- NCT05485077
- Where
- China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Singlera Genomics Inc.
Pancreatic Cancer
DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer
Based on the cell free nucleic acid analysis information of blood samples and genetic mutation profile of EUS-FNB tissue from pancreatic cancer, the concordance between them is evaluated.
- Trial name
- NCT05604573
- Testing
- cell free DNA in blood, genetic mutation in tissue
- Where
- South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
Circulating free cell DNA (cfDNA) is extracellular fragmentation of nucleic acids that occurs both in plasma and serum. This kind of DNA which derived from the apoptotic/necrotic cells or the lysis of circulating tumor cells…
- Trial name
- NCT02036216
- Where
- 2 sites in United States, China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Non-small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT02838836
- Testing
- Study sample collection
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Pulmonary Nodules
Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules
AnchorDx is using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS) to develop a blood-based assay for differentiating benign and malignant pulmonary nodules early.
- Trial name
- NCT03651986
- Testing
- ctDNA methylation analysis by NGS
- Where
- 23 sites in China
- Volunteers
- 10,560 people, healthy volunteers welcome
- Sponsor
- AnchorDx Medical Co., Ltd.
Cancer, Breast Cancer
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the…
- Conditions
- Cancer, Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- LIBERATE (NCT03702309)
- Where
- Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Colorectal Cancer Screening
Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
The purpose of this study is to collect clinical specimens from subjects with a diagnosis of colorectal cancer/advanced adenoma or undergoing a screening colonoscopy and meeting study eligibility criteria.
- Trial name
- NCT05127096
- Testing
- FirstSight blood test
- Where
- 15 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CellMax Life
Colorectal Cancer, Advanced Adenoma
Diagnosis of Colorectal Cancer and Advanced Adenoma Using Cancer-specific Methylation Signatures
Colorectal cancer is a common malignant tumor of the digestive tract. It is still a challenging task to detect colorectal cancer at an early stage.
- Trial name
- NCT03828396
- Where
- China
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Non-small Cell Lung Cancer
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported.
- Trial name
- FOCUS-C (NCT05334277)
- Testing
- Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
- Where
- 26 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Thoracic Cancer, Ovarian Cancer
Project CADENCE (CAncer Detected Early caN be CurEd)
With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be…
- Conditions
- Thoracic Cancer, Ovarian Cancer, Liver Cancer, Prostate Cancer
- Trial name
- CADENCE (NCT05633342)
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- MiRXES Pte Ltd
Preoperative and Postoperative ctDNA Comparison in Early Stage Lung Cnacer
Preoperative and Postoperative ctDNA Comparison in Early Stage Lung Cancer
Mutation-positive peripheral blood ctDNA became mutation-negative after surgical removal of the cancer tissue. All subjects in the control group were negative for ctDNA mutations。
- Trial name
- NCT03805256
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Soochow University
Stomach Neoplasms, Circulating Tumor DNA
Methylation Analysis of Circulating Tumor DNA in Gastric Cancer
The primary purpose of this trial is to describe the profile of ctDNA methylation in gastric cancer. The second purpose is to demonstrate the correlation between the plasma ctDNA methylation status and the diagnosis and prognosis…
- Trial name
- NCT04511559
- Testing
- Circulating Tumor DNA Methylation Sequencing, tissue DNA Methylation Sequencing
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Cancer
Clinical Validation of ColonAiQ (a Blood-based Assay Targeting ctDNA Methylation) for Colorectal Cancer Detection
The DNA methylation targets in preoperative plasma samples of the subjects will be detected by the multi-gene methylation test (ColonAiQ), and the test accuracy will be evaluated by compared with the clinical diagnosis evidence.
- Trial name
- NCT06347887
- Testing
- ColonAiQ test and Colonoscopy
- Where
- 7 sites in China
- Volunteers
- 1,965 people, healthy volunteers welcome
- Sponsor
- Singlera Genomics Inc.
Early Detection of Cancer, Cancer
PATHFINDER 2: A Multi-Cancer Early Detection Study
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America.
- Trial name
- NCT05155605
- Testing
- Multi-Cancer Early Detection Test
- Where
- 56 sites in United States, Canada
- Volunteers
- 35,883 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.